SCHEMBL4140802

SCHEMBL4140802

CCOc1ccccc1C(=O)Nc1sc(C)c(C)c1C(N)=O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.56
ALDH1A1 P00352 10/20 0.56
KDM4E B2RXH2 4/20 0.56
HPGD P15428 3/20 0.56
LMNA P02545 3/20 0.56
RAB9A P51151 5/20 0.54
SMN1; SMN2 Q16637 4/20 0.54
TP53 P04637 2/20 0.54
MAPK10 P53779 1/20 0.54
HSD17B10 Q99714 1/20 0.54
FLT3 P36888 1/20 0.54
MAPT P10636 6/20 0.53
NPC1 O15118 4/20 0.53
GAA P10253 3/20 0.53
MEN1 O00255 2/20 0.53
USP2 O75604 1/20 0.52
MAPK1 P28482 2/20 0.51
NFKB1 P19838 1/20 0.51
CASP1 P29466 1/20 0.51
CASP7 P55210 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8288650 0.79 ALDH1A1 (0.68) KMT2AALDH1A1KDM4EHPGDLMNA
SCHEMBL6996786 0.77 FLT3 (0.70) KMT2AALDH1A1KDM4EHPGDRAB9A
SCHEMBL7165819 0.76 MAPT (0.63) KMT2AALDH1A1KDM4EHPGDLMNA
SCHEMBL7003777 0.76 ALDH1A1 (0.62) KMT2AALDH1A1KDM4EHPGDLMNA
SCHEMBL7005515 0.75 L3MBTL1 (0.65) KMT2AALDH1A1KDM4EHPGDLMNA
SCHEMBL7167114 0.75 MAPT (0.60) KMT2AALDH1A1LMNARAB9ASMN1; SMN2
SCHEMBL7002469 0.75 ALDH1A1 (0.60) KMT2AALDH1A1KDM4EHPGDLMNA
SCHEMBL3018829 0.74 MEN1 (0.53) KMT2AALDH1A1RAB9ASMN1; SMN2TP53
SCHEMBL3029893 0.73 MAPT (0.50) KMT2AALDH1A1KDM4ERAB9ATP53
SCHEMBL7160571 0.73 MAPT (0.55) KMT2AALDH1A1RAB9ASMN1; SMN2TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090143411-A1 Thiophens and Their Use as Anti-Tumor Agents COMPASS PHARMACEUTICALS LLC (US) 2009-06-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143411-A1 Thiophens and Their Use as Anti-Tumor Agents TP53, BRDT, VHL KMT2A 3189/4885ALDH1A1 1202/4885KDM4E 2942/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.